abstract |
Antibodies comprising at least one Fab portion that binds CD47 and at least one Fab portion that binds tumor associated antigen (TAA) CD20 are provided; The Fab portion that binds to CD47 exhibits low affinity for CD47; The Fab portion that binds to CD20 exhibits high affinity for CD20; The antibody selectively binds to CD47 in tumor cells and blocks CD47 interaction with SIRPĪ±, but shows no substantial binding to CD47 in normal cells. |